January 13, 2020 11:31 AM EST
Deals

Ahead of ad­u­canum­ab fil­ing, Bio­gen nabs Pfiz­er castoff for $75M to ad­dress Alzheimer's, Parkin­son's symp­toms

Amber Tong

Bio­gen be­lieves (not every­one agrees) it has a dis­ease-mod­i­fy­ing ther­a­py for Alzheimer’s on the cusp of an FDA ap­proval. Now it’s bring­ing in an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

A service from the Financial Times